Lubrizol debuts paraben alternative
This article was originally published in The Rose Sheet
Executive Summary
With the negative perception of paraben and formaldehyde preservatives in the marketplace, and shift to food-grade preservatives like sodium benzoate, Lubrizol Corporation releases Carbopol Aqua SF-2 polymer. Product is a "rheology modifier" that "delivers high clarity and superior suspension in the 4 to 6 pH range," says the Cleveland, Ohio-based company in a Sept. 13 release. Product will accommodate natural preservatives that require a pH level near 5 without sacrificing formulation clarity or flow properties, according to Lubrizol. "Now formulators can display colorful beads, sparkling pearls and exfoliating scrubs while also achieving claims of 'paraben-free,' 'formaldehyde-free,' 'preservative-free' and even 'skin neutral pH,'" firm explains. Potential uses for the polymer include clear bath gels, body scrubs with suspended microcapsules, facial scrubs with exfoliating beads, anti-acne facial cleansers with salicylic acid, pearlescent shampoos and soap-based cleansers
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.